# A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT02760485** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 33 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** itacitinib
- **DRUG:** ibrutinib

## Key facts

- **NCT ID:** NCT02760485
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-29
- **Primary completion:** 2022-06-06
- **Final completion:** 2022-06-06
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02760485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02760485, "A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02760485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*